Group 1 - The company Meihua Biological (SH 600873) announced a share buyback of 35.7084 million shares, representing 1.25% of its total share capital of approximately 2.853 billion shares, with a total expenditure of about 352 million RMB [1][1][1] - The share buyback was conducted through centralized bidding, with the lowest purchase price at 9.1 RMB per share and the highest at 10.68 RMB per share, complying with legal regulations and the company's buyback plan [1][1][1] - As of the report date, the market capitalization of Meihua Biological is 31.3 billion RMB [1][1][1] Group 2 - For the fiscal year 2024, the revenue composition of Meihua Biological is as follows: 97.34% from bio-fermentation, 1.9% from pharmaceutical health, and 0.76% from other businesses [1][1][1]

梅花生物科技集团股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600873 证券简称：梅花生物 公告编号：2025-053 重要内容提示： 回购方案首次披露日 2024/9/24，由公司董事长王爱军提议 回购方案实施期限 2024 年 10 月 11 日~2025 年 10 月 10 日 预计回购金额 30,000万元~50,000万元 √减少注册资本 □用于员工持股计划或股权激励 回购用途 □用于转换公司可转债 □为维护公司价值及股东权益 累计已回购股数 3,570.84万股 累计已回购股数占总股本比例 1.25% 累计已回购金额 35,202.44万元 实际回购价格区间 9.10元/股~10.68元/股 一、 回购股份的基本情况 梅花生物科技集团股份有限公司（以下简称"公司"）分别于 2024 年 9 月 23 日、2024 年 10 月 11 日召开了公司第十届董事会第十三次会议和 2024 年第二次临 时股东大会，会上审议通过了《关于以集中竞价交易 ...

证券代码：600873 证券简称：梅花生物 公告编号：2025-053 梅花生物科技集团股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 三、其他事项 重要内容提示： 一、回购股份的基本情况 梅花生物科技集团股份有限公司（以下简称"公司"）分别于 2024 年 9 月 23 日、2024 年 10 月 11 日召开了公司第十届董事会第十三次会议和 2024 年第二次临 时股东大会，会上审议通过了《关于以集中竞价交易方式回购公司股份的议案》。 公司于 2024 年 10 月 12 日披露了《梅花生物科技集团股份有限公司关于以集中竞 价交易方式回购股份的回购报告书》，本次回购金额不低于人民币 3 亿元，不超过 人民币 5 亿元，回购股份用于注销，减少注册资本。2024 年 10 月 23 日，公司实 施了首次回购。具体内容详见公司披露在上海证券交易所网站（www.sse.com.cn） 上的相关公告。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市 ...

Core Insights - The report emphasizes that the chemical industry is entering a new phase of capital expenditure, with a focus on the rebalancing of supply and demand following the release of production capacity during the 14th Five-Year Plan period [2][6] - The report indicates that the bottom of the cycle is becoming clearer, with potential price increases for chemical products driven by demand recovery and supply stability in the second half of the year [2][6] Industry Overview - The current cycle has reached its tail end, with a total of 12 quarters of decline since Q3 2022, following a 7-quarter expansion from Q4 2020 to Q2 2022 [10][12] - The report outlines that the chemical industry has experienced three significant price fluctuation cycles since 2010, with the latest cycle characterized by a demand-driven recovery followed by a supply-side pressure [8][10] Investment Recommendations - The report suggests focusing on sectors with relatively low valuations, such as sucralose (recommended: Jinhe Industrial), pesticides (recommended: Yangnong Chemical, Runfeng Shares), and MDI (recommended: Wanhua Chemical) [3][4] - It highlights the importance of domestic demand in countering tariff impacts, recommending companies in refrigerants and fertilizers [3][4] - The report identifies investment opportunities in sectors with upcoming capacity releases, such as organic silicon (recommended: Xin'an Chemical) and spandex [3][4] Price and Profitability Trends - The report notes that many sub-industry product prices remain at historical lows, with specific prices for spandex, PA6, and other fibers at 0%, 4%, and 5% of historical levels respectively [28] - It mentions that the chemical industry has seen a slight recovery in profitability in Q1 2025, although the overall performance remains under pressure [27][25] Supply and Demand Dynamics - The report indicates that the global chemical capital expenditure is on a downward trend, with domestic companies experiencing a slowdown in investment while still facing significant pressure to convert projects into fixed assets [22][32] - It also states that both domestic and international markets are entering a replenishment phase in 2025, which may influence inventory levels and pricing strategies [35][36]

Overview - Tryptophan is an essential amino acid that cannot be synthesized by the human body and must be obtained through food [2][4] - The market demand for tryptophan has rapidly increased due to the development of the livestock industry and the "reduction of soybean meal substitution" policy [4][9] - In 2024, the demand for tryptophan in China is projected to reach 23,800 tons, with a market size of 1.309 billion yuan [4][9] Market Policy - The Chinese government has issued several policies to support the development of the amino acid industry, including the "14th Five-Year Plan" and various guidelines for the pharmaceutical and feed industries [4][5] Industry Chain - The upstream of the tryptophan industry includes suppliers of raw materials like corn and molasses, while the midstream involves the production of tryptophan, and the downstream encompasses applications in feed, pharmaceuticals, health products, and food [6][7] Current Development - The feed sector accounts for over 70% of the demand for tryptophan in China, with industrial feed production expected to reach 158.5 million tons in the first half of 2025, a year-on-year increase of 7.7% [9][10] - The increasing focus on health foods has led to a rise in the use of tryptophan as a nutritional supplement for improving sleep and emotional balance [4][9] Competitive Landscape - The market concentration of tryptophan has increased, with international companies like Ajinomoto and CJ Cheiljedang holding significant market shares, while domestic companies such as Ningxia Yipin Biotechnology and Anhui Huaheng Biological Technology are gaining ground through innovation and resource advantages [10][11] Key Players - Fujian Group is a major player in the tryptophan market, with projected revenues of 27.76 billion yuan and a gross profit of 5.057 billion yuan in 2024 [12] - Anhui Huaheng Biological Technology focuses on synthetic biology and expects revenues of 2.178 billion yuan in 2024, with amino acid products contributing 69.28% of total revenue [12][13] Future Trends - The production of tryptophan is primarily through microbial fermentation, with future advancements expected in genetic engineering to enhance production efficiency and product purity [14] - There is a growing emphasis on green production processes to reduce costs and environmental impact, aligning with stricter environmental regulations [14]

Group 1 - The consumer sector has recently seen significant inflows, with over 3.4 billion yuan into consumer-themed ETFs since August, contrasting sharply with earlier in the year when technology stocks were favored [1] - The current price-to-earnings (P/E) ratio of the major consumer index is 19.88, which is below the three-year average of 30%, suggesting a perceived valuation advantage [4] - The experience of the past indicates that low valuation does not guarantee price increases, as market consensus and large capital movements are more decisive factors [4] Group 2 - Institutional behavior is crucial in understanding market dynamics, as evidenced by the sustained investment in bank stocks since 2022 despite high valuation concerns [5][7] - The lack of institutional participation in the liquor sector has led to continuous price declines, highlighting the importance of large capital involvement for price recovery [10] - The consumer sector's recent activity may indicate a strategic reallocation of funds, similar to past movements in bank stocks, suggesting that large investors are quietly positioning themselves [11] Group 3 - The current fluctuations in the consumer sector raise questions about whether this is a valuation correction or the beginning of a new market trend, with institutional inflows being a critical signal to monitor [13]

Core Viewpoint - On August 25, 2023, brokerage firms provided target prices for listed companies, with notable increases in target prices for companies in the agriculture, coal mining, and construction materials sectors, indicating potential investment opportunities in these industries [1][2]. Target Price Increases - The companies with the highest target price increases were: - Longping High-Tech (隆平高科) with a target price increase of 38.75% to 14.00 CNY [2] - Xinji Energy (新集能源) with a target price increase of 37.40% to 9.00 CNY [2] - Beixin Building Materials (北新建材) with a target price increase of 36.57% to 36.90 CNY [2] Brokerage Recommendations - A total of 163 listed companies received brokerage recommendations on August 25, with notable mentions: - Shede Liquor (舍得酒业) received 4 recommendations [4] - Shuiyang Co. (水羊股份) and Marubi Biotechnology (丸美生物) each received 3 recommendations [4] Rating Adjustments - One company had its rating upgraded: - Guodian Power (国电电力) was upgraded from "Hold" to "Buy" by Huayuan Securities [5] - Three companies had their ratings downgraded: - Minhe Livestock (民和股份) from "Buy" to "Hold" [6] - Chifeng Gold (赤峰黄金) from "Buy" to "Hold" [6] - Silan Microelectronics (士兰微) from "Buy" to "Hold" [6] First-Time Coverage - Seven companies received first-time coverage with positive ratings: - Ganhua Science and Technology (甘化科工) received a "Buy" rating from Dongwu Securities [7] - Wangneng Environment (旺能环境) received a "Buy" rating from Xinda Securities [7] - Yingliu Co. (应流股份) received an "Increase" rating from Shanxi Securities [7] - New Clean Energy (新洁能) received an "Increase" rating from Industrial Securities [7] - Weijian Medical (稳健医疗) received a "Buy" rating from Northeast Securities [7]

Investment Rating - Investment rating is maintained as "Buy" [2] Core Views - In H1 2025, the company achieved operating revenue of 12.28 billion yuan, a year-on-year decrease of 2.87%, while net profit attributable to shareholders reached 1.768 billion yuan, an increase of 19.96% year-on-year [5][6] - The decline in revenue was offset by a significant reduction in raw material costs and increased sales volume, leading to a notable improvement in profitability [6] - The company completed the acquisition of Kyowa Hakko Bio's amino acid and HMO businesses, enhancing its product matrix and expanding its overseas production bases [8][9] Financial Performance - For Q2 2025, the company reported operating revenue of 6.012 billion yuan, a year-on-year decrease of 2.34%, and a net profit of 749 million yuan, a year-on-year increase of 3.76% [7] - The average price of key products such as lysine and valine experienced declines, impacting revenue, but the overall sales volume remained stable [7] - The average price of corn, a core raw material, decreased by 6.78% year-on-year, contributing to improved margins [6] Future Outlook - The company is expected to achieve net profits of 3.448 billion yuan, 3.627 billion yuan, and 3.934 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 25.8%, 5.2%, and 8.5% [10] - The projected P/E ratios for the next three years are 9, 9, and 8 times, indicating a favorable valuation [10]

Investment Rating - The report maintains a "Buy" investment rating for Meihua Biological (600873.SH) [1] Core Views - Meihua Biological is a leading enterprise in the amino acid industry, successfully completing cross-border mergers and acquisitions [1] - The company achieved a total operating revenue of 12.28 billion yuan in the first half of 2025, a year-on-year decrease of 2.87%, while net profit attributable to shareholders increased by 19.96% to 1.768 billion yuan [4][5] - The company is expected to see steady growth in performance due to rapid release of new production capacity, with projected net profits for 2025-2027 being 3.106 billion, 3.524 billion, and 3.905 billion yuan respectively [9] Summary by Sections Market Performance - The stock price of Meihua Biological is currently at 11.01 yuan, with a total market capitalization of 31.4 billion yuan [1] Financial Performance - In Q2 2025, the company reported an operating revenue of 6.012 billion yuan, a year-on-year decrease of 2.34% and a quarter-on-quarter decrease of 4.09% [4] - The company’s gross profit increased by 382 million yuan, contributing to the rise in net profit [5] Product and Cost Management - The sales volume of the main products, including monosodium glutamate and 98% lysine, increased, with 70% of lysine experiencing both volume and price increases [5] - Management expenses decreased primarily due to reduced consulting and labor costs, while operating cash flow showed a net increase of 3.44% compared to the same period last year [6] Global Expansion and Competitive Position - The company has made significant progress in capacity expansion, with the Tongliao monosodium glutamate capacity upgrade project reaching full production [7] - The acquisition of a Japanese company in July 2025 has allowed the company to extend its industrial chain into high-value downstream pharmaceutical-grade amino acids and HMO business lines [8] Profit Forecast - The projected P/E ratios for 2025-2027 are 10.1, 8.9, and 8.0 times respectively, indicating a favorable valuation for investors [9]

Resource Overview - Tongliao City has identified coal reserves of 11 billion tons, natural soda reserves of approximately 2.077 billion tons, and rock salt resources of 1.56 billion tons, providing a solid foundation for the development of the chemical new materials industry [1] - The city produces over 8 billion kilograms of high-quality corn annually, which supports the corn-based biochemistry and biopharmaceutical industries [1] Industrial Development - Tongliao is optimizing its industrial structure by developing new coal chemical, corn biochemistry, and other industrial clusters, with several industrial parks recognized as chemical concentration areas by the Inner Mongolia government [1] - The Zhonghua Chemical (Inner Mongolia) New Materials Co., Ltd. has established a project with an annual production capacity of 300,000 tons of coal-based ethylene glycol, transforming traditional coal chemical perceptions [2][3] Economic Impact - The ethylene glycol project has attracted an investment of 6.414 billion yuan, expected to generate an annual output value exceeding 1.5 billion yuan and create 2,000 jobs [3] - The local government has invested approximately 2.1 billion yuan in infrastructure to support the project, revitalizing previously idle facilities [3] Corn Biochemical Industry - Tongliao's corn production accounts for 28.8% of Inner Mongolia's total and 3.05% of the national total, with a focus on developing a complete corn biopharmaceutical industry chain [4][5] - The Kaidu Biopharmaceutical Development Zone aims to become the largest corn fermentation base in the country, with 106 enterprises established, producing over 350 million tons of processed corn annually [5] Renewable Energy Integration - Tongliao has a total installed capacity of 14.1 million kilowatts of renewable energy, accounting for 59.68% of the city's total power capacity, facilitating the green transformation of the chemical industry [6][7] - The city is developing integrated projects that couple renewable energy with chemical production to reduce carbon emissions and support the "dual carbon" goals [7] Specialty Industries - The city is focusing on developing specialty industries, including salt and soda chemical industries, leveraging its abundant natural resources [8][9] - The Naiman Banner has over 2 billion tons of identified natural soda resources, which are expected to attract downstream industries and enhance the overall competitiveness of the chemical sector [9]